

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1483PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/737,544
		Filing Date	12/18/2000
		First Named Inventor	MARK B PEPYS
		Art Unit	1617
		Examiner Name	Wang, S.
Sheet 1 of 1	Attorney Docket Number	068800-0276486	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SW	A	BHAKDI ET AL., "Possible Protective Role for C-Reactive Protein in Atherogenesis," <i>Circulation</i> , p. 1870-1876, (2004a).	
SW	B	BHAKDI ET AL., "Beyond cholesterol: the enigma of atherosclerosis revisited," <i>Thromb. Haemost.</i> , p. 639-645, (2004b).	
SW	C	VADAS ET AL., "Inhibition of human group II phospholipase A2 by C-reactive protein in vitro," <i>J. Lipid Mediat. Cell Signal</i> , Vol. 11 (No. 2), p. 187-200 (abstract only), (1995).	
SW	D	TSUJIMOTO ET AL., "C-Reactive protein induced agglutination of lipid suspensions prepared in the presence and absence of phosphatidylcholine," <i>J. Biochem.</i> , Vol. 87 (No. 5), p. 1531-7 (abstract only), (1980).	
SW	E	MORI ET AL., "Involvements of fibronectin and lysophosphatidylcholine for selective binding of c-reactive protein," <i>Cell Mol Biol.</i> , Vol. 37 (No. 4), p. 421-31 (abstract only), (1991).	
SW	F	CHANG ET AL., "C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , Vol. 99 (No. 20), p. 13043-8, (2002).	
SW	G	GILL ET AL., "Human C-Reactive Protein Increases Cerebral Infarct Size After Middle Cerebral Artery Occlusion in Adult Rats," <i>J. Cerebral Blood Flow & Metabolism</i> , Vol. 24 (No. 11), p. 1214-1218, (November 2004).	

Examiner Signature	S. C. D.	Date Considered	8/30/05
--------------------	----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.